FindTrial
Sign In

Comparison of Prognosis and Safety between Neoadjuvant Combined Surgery and Direct Surgery for Resectable HCC Patients in CNLC Stages ?b-?a, and Stratified Analysis of Neoadjuvant Strategies

Comparison of survival benefit and safety between target-oriented neoadjuvant therapy + surgery and direct surgery in patients with resectable HCC in stages CNLC?b-?a

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119979
Enrollment
Unknown
Registered
2026-03-06
Start date
2026-03-07
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Neoadjuvant therapy group:None
Surgery alone group:None

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Postoperative pathological diagnosis confirmed primary hepatocellular carcinoma; 3. Hepatocellular carcinoma, CNLC stage ?b-?a; 4. Undergo radical hepatic resection (R0 resection); 5. Meet the criteria for "resectability".

Exclusion criteria

Exclusion criteria: 1. Concurrent presence of other primary malignant tumors; 2. HCC patients who have undergone previous treatments such as liver resection and ablation and have experienced recurrence; 3. Cases with incomplete clinical information; 4. It does not meet the "resectable" criteria.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival time;Overall survival time;—

Countries

China

Contacts

Public ContactLin Chen

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

chenlin_tj@126.com+86 135 1726 0864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026